The test can be used in conjunction with other FDA-cleared Lyme enzyme immunoassays developed by GSD as part of a CDC-recommended modified two-tiered testing algorithm.
The coalition includes partners from all over the world, including universities, research centers, and health systems in South Asia, Africa, South America, and the US.
The company said the test can be used to evaluate effective antibody levels after SARS-CoV-2 infection or vaccination, as well as to assess adaptive immunity.
The firm's assay leverages reverse transcriptase quantitative PCR to amplify two separate regions of the HIV-1 genome to monitor HIV-infected patients.
The firm said the new contract will provide funding to support the production of up to 6.7 million COVID-19 antigen and antibody tests per month for the US market.
FIND aims to make easy-to-use self-tests available in low- to middle-income countries and has set aside an initial budget of $15 million for the initiative.
The program, which will provide supplies of rapid, at-home antigen tests, aims to determine if frequent self-testing can reduce community transmission of the virus.
Osang previously granted nonexclusive US distribution rights to the PCR-based test to SG Blocks and has a manufacturing arrangement for the test with Nexus Dx.
Amazon said that it will use its test for employees and other individuals who enter its facilities as part of its COVID-19 preparedness and response program.
